Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

NCT02137772 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

570

Enrollment

INDUSTRY

Sponsor class

Conditions

Prevention of CMV Infection or Disease

Interventions

DRUG: Letermovir
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC